William Smith

The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector

/0 Comments/in , , /by William Smith
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

Download Report: The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector